N. Todor
CancerInternal medicineRadiologyUrologySurgeryOncologyRetrospective cohort studyProspective cohort studyChemotherapyPerformance statusCervical cancerCisplatinConcomitantRegimenToxicityLocally advancedConcurrent chemoradiotherapyPhases of clinical researchRadiation therapyColorectal cancerMedicineGastroenterology
43Publications
9H-index
163Citations
Publications 62
Newest
#4Diana Cristina PopH-Index: 2
#6Claudia OrdeanuH-Index: 7
Last. Ovidiu CozaH-Index: 8
view all 20 authors...
Introduction/Background* null The purpose of this study was to evaluate 5-year overall survival (OS), disease free survival (DFS) and local control (LC) for patients diagnosed with primary vulvar cancer and treated at Institute of Oncology “Prof.Dr.Ion Chiricuta” Cluj-Napoca, Romania. null Methodology null Between 2010 and 2019 a number of 306 patients with vulvar cancer were treated in our institution, from which we included in this retrospective study 233 patients with squamous cell vulvar can...
Source
Source
Source
Purpose Multiple primary neoplasms (MPN) have a growing impact in the outcome of oncological patients given the rising incidence of these entities in daily practice. The early diagnosis of secondary tumors could translate into better survival of patients with MPN. The final objective of this study was the elaboration of a follow-up protocol for oncological patients at risk of developing multiple primary neoplasms. Methods Patients with MPN diagnosed and treated in the Oncology Institute "Prof.Dr...
PURPOSE: To evaluate differences between the data from project "Surveillance of Rare Cancers in Europe" (RARECARENet) and the data from the Institute of Oncology "Prof.Dr. Ion Chiricuta" (IOIC). METHODS: Data from institutional cancer registry of IOIC through 2012 to 2013 and the data published in RARECARENet project were compared. RESULTS: There were 14,127 cases in the IOIC cancer registry but only 13632 were compliant with the RARECARENet categories. Of these 7382 (54%) are common, 5975 (44%)...
#1Patricia ȘuteuH-Index: 1
#2N. TodorH-Index: 9
Last. Viorica NagyH-Index: 6
view all 4 authors...
: Aim: To identify prognostic factors of survival in patients with brain metastases (BM) and to devise a prognostic score. Patients & methods: In this single-institution retrospective study, we analyzed potential clinical prognostic factors in 1363 patients with BM. Based on the Cox proportional hazard model, we devised a BM score with three classes (score 6). Results: The 1-year overall survival (OS) was 26%. Independent prognostic factors of OS were: age, gender, Karnofski performance status, ...
Source
#1Patricia SuteuH-Index: 1
#2Zsolt Fekete (Iuliu Hațieganu University of Medicine and Pharmacy)H-Index: 6
Last. Viorica NagyH-Index: 6
view all 4 authors...
Background. Brain metastases are the most frequent intracranial neoplasms in adults. Although overall survival (OS) is an important endpoint in patients receiving radiotherapy, given their poor life expectancy in general, quality of life is becoming an increasingly useful endpoint. Objectives: to evaluate whole brain radiotherapy (WBRT) with 3D conformal boost in brain metastases patients with regard to OS and quality of life. Methods. During April 2015-May 2017, a total of 35 patients with ≤5, ...
Source
PURPOSE: Multiple primary neoplasms (MPN) represent the occurrence of two or more primary neoplasms in the same individual during lifetime and today there is an increased interest in studying the implications of MPN in the outcome of oncological patients. In this study we aimed to evaluate the clinicopathological characteristics of patients with MPN. METHODS: In this nonrandomized, retrospective study patients with MPN treated in the Oncology Institute "Prof.Dr.Ion Chiricuta" Cluj-Napoca between...
#2Dan EniuH-Index: 7
Last. Zsolt FeketeH-Index: 6
view all 9 authors...
Source
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.